Klin Monbl Augenheilkd 2010; 227(2): R15-R28
DOI: 10.1055/s-0029-1240867
KliMo-Refresher
Rubrikherausgeber: G. Duncker, Halle
© Georg Thieme Verlag KG Stuttgart · New York

Neovaskularisationsglaukom

R. A. Widder1 , K.-D. Lemmen1 , T. S. Dietlein2
  • 1Augenklinik des St. Martinus-Krankenhauses, Düsseldorf
  • 2Zentrum für Augenheilkunde der Universität zu Köln
Further Information

Publication History

Publication Date:
12 February 2010 (online)

Einleitung

Neovaskularisationsglaukome sind eine große Herausforderung. Sie treten meist im Spätstadium einer Vielzahl von Gefäßerkrankungen der Netzhaut auf, die als gemeinsame Endstrecke eine ischämisch-proliferative Retinopathie entwickelt haben. Ihre Prognose ist ernst, immerhin erfolgen 12–15 Prozent aller Enukleationen wegen eines neovaskulären Glaukoms [4].

Entsprechend vielfältig sind die Anforderungen an eine effektive Behandlung, die ein optimiertes Patientenmanagement an der Schnittstelle zwischen Glaukomatologie und Retinologie erfordert:

Wie können derartige Verläufe frühzeitig erkannt und ihre Komplikationen vermieden werden? Welche drucksenkenden Konzepte (medikamentöse Glaukomtherapie, zyklodestruktive Glaukomchirurgie, filtrierende Glaukomchirurgie, Drainage-Implantate) sind bei diesen speziellen Patienten anwendbar? Welche retinologischen Behandlungskonzepte (panretinale Laserkoagulation, intravitreale oder intrakamerale Injektionen, Pars-plana-Vitrektomie) müssen primär durchgeführt oder parallel eingeleitet werden?

Literatur

  • 1 The Diabetic Retinopathy Study Research Group . Indications for photocoagulation treatment of diabetic retinopathy.  Int Ophthalmol Clin. 1987;  27 239-253
  • 2 The Central Vein Occlusion Study Group . Natural history and clinical management of central retinal vein occlusion.  Arch Ophthalmol. 1997;  115 486-491
  • 3 Macugen Retinopathy Diabetic Study Group . Changes in retinal neovascularisation after pegaptanib (macugen) therapy in diabetic individuals.  Ophthalmology. 2006;  113 23-28
  • 4 Agostini H J, Funk J. Neovaskuläres Glaukom. Schlote TRJ Sekundärglaukome. Stuttgart; Schattauer 2004: 237-248
  • 5 Aiello L P, Avery R L, Arrigg P G et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.  N Engl J Med. 1994;  331 1480-1487
  • 6 Arevalo J F, Wu L, Sanchez J G et al. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up.  Eye. 2009;  23 117-123
  • 7 Brown G C, Magargal L E, Schachat A et al. Neovascular glaucoma. Etiologic considerations.  Ophthalmology. 1984;  91 315-320
  • 8 Brown G C, Shah H G, Magargal L E et al. Central retinal vein obstruction and carotid artery disease.  Ophthalmology. 1984;  91 1627-1633
  • 9 Brown G C, Brown M M. The ocular ischemic syndrome. Joussen AM, Gardner T, Kirchhof B, Ryan SJ Retinal vascular disease. Heidelberg; Springer 2007: 519-527
  • 10 Browning D J, Scott A Q, Peterson C B et al. The risk of missing angle neovascularization by omitting screening gonioscopy in acute central retinal vein occlusion.  Ophthalmology. 1998;  105 776-784
  • 11 Burton M G Z. Retinal artery occlusion. Joussen AM, Gardner T, Kirchhof B, Ryan SJ Retinal vascular disease. Heidelberg; Springer 2007: 507-518
  • 12 Caprioli J, Strang S L, Spaeth G L et al. Cyclocryotherapy in the treatment of advanced glaucoma.  Ophthalmology. 1985;  92 947-954
  • 13 Dietlein T S, Hermann M M, Jordan J F. The medical and surgical treatment of glaucoma.  Dtsch Arztebl Int. 2009;  106 597-605 quiz 606
  • 14 Eid T E, Katz L J, Spaeth G L et al. Tube-shunt surgery versus neodymium:YAG cyclophotocoagulation in the management of neovascular glaucoma.  Ophthalmology. 1997;  104 1692-1700
  • 15 Eid T M, Radwan A, el-Manawy W et al. Intravitreal bevacizumab and aqueous shunting surgery for neovascular glaucoma: safety and efficacy.  Can J Ophthalmol. 2009;  44 451-456
  • 16 Fakhraie G, Katz L, Prasad A et al. Surgical outcomes of intravitreal bevacizumab and guarded filtration surgery in neovascular glaucoma.  Journal of Glaucoma. 2009;  , Epub ahead of print
  • 17 Falavarjani K, Modarres M, Nazari H. Therapeutic effect of bevacizumab injected into the silicone oil in eyes with neovascular glaucoma after vitrectomy for advanced diabetic retinopathy.  Eye. 2009;  , Epub ahead of print
  • 18 Grisanti S, Biester S, Peters S et al. Intracameral bevacizumab for iris rubeosis.  Am J Ophthalmol. 2006;  142 158-160
  • 19 Grover S, Gupta S, Sharma R et al. Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma.  Br J Ophthalmol. 2009;  93 273-274
  • 20 Iliev M E, Domig D, Wolf-Schnurrbursch U et al. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma.  Am J Ophthalmol. 2006;  142 1054-1056
  • 21 Joussen A M, Adamis A P. Inflammation as a stimulus for vascular leakage and proliferation. Joussen AM, Gardner T, Kirchhof B, Ryan SJ Retinal vascular disease. Heidelberg; Springer 2007: 97-107
  • 22 Katz G J, Higginbotham E J, Lichter P R et al. Mitomycin C versus 5-fluorouracil in high-risk glaucoma filtering surgery. Extended follow-up.  Ophthalmology. 1995;  102 1263-1269
  • 23 Lang G E. Laser treatment of diabetic retinopathy.  Dev Ophthalmol. 2007;  39 48-68
  • 24 Lim T H, Bae S H, Cho Y J et al. Concentration of vascular endothelial growth factor after intracameral bevacizumab injection in eyes with neovascular glaucoma.  Korean J Ophthalmol. 2009;  23 188-192
  • 25 Lin S C. Endoscopic and transscleral cyclophotocoagulation for the treatment of refractory glaucoma.  J Glaucoma. 2008;  17 238-247
  • 26 Madsen P H. Haemorrhagic glaucoma. Comparative study in diabetic and nondiabetic patients.  Br J Ophthalmol. 1971;  55 444-450
  • 27 Mason J O, Albert M A, Mays A et al. Regression of neovascular iris vessels by intravitreal injection of bevacizumab.  Retina. 2006;  26 839-841
  • 28 Matsuyama K, Ogata N, Jo N et al. Levels of vascular endothelial growth factor and pigment epithelium-derived factor in eyes before and after intravitreal injection of bevacizumab.  Jpn J Ophthalmol. 2009;  53 243-248
  • 29 Mermoud A, Salmon J F, Alexander P et al. Molteno tube implantation for neovascular glaucoma. Long-term results and factors influencing the outcome.  Ophthalmology. 1993;  100 897-902
  • 30 Mizener J B, Podhajsky P, Hayreh S S. Ocular ischemic syndrome.  Ophthalmology. 1997;  104 859-864
  • 31 Molteno A C, Haddad P J. The visual outcome in cases of neovascular glaucoma.  Aust N Z J Ophthalmol. 1985;  13 329-335
  • 32 Ohnishi Y, Ishibashi T, Sagawa T. Fluorescein gonioangiography in diabetic neovascularisation.  Graefes Arch Clin Exp Ophthalmol. 1994;  232 199-204
  • 33 Ohrt V. The frequency of rubeosis iridis in diabetic patients.  Acta Ophthalmol (Copenh). 1971;  49 301-307
  • 34 Oshima Y, Sakaguchi H, Gomi F et al. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy.  Am J Ophthalmol. 2006;  142 155-158
  • 35 Rüfer F, Roider J. General concepts in laser treatment for retinal vascular disease. Joussen AM, Gardner T, Kirchhof B, Ryan SJ Retinal vascular disease. Heidelberg; Springer 2007: 3309-3341
  • 36 Saito Y, Higashide T, Takeda H et al. Beneficial effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes in neovascular glaucoma.  Acta Ophthalmol. 2009;  , Epub ahead of print
  • 37 Schlote T, Bartz-Schmidt K U. Treatment of rubeotic secondary glaucoma. Joussen AM, Gardner T, Kirchhof B, Ryan SJ Retinal vascular disease. Heidelberg; Springer 2007: 274-282
  • 38 Scott I U, Alexandrakis G, Flynn H W et al. Combined pars plana vitrectomy and glaucoma drainage implant placement for refractory glaucoma.  Am J Ophthalmol. 2000;  129 334-341
  • 39 Shields M B, Shields S E. Noncontact transscleral Nd:YAG cyclophotocoagulation: a long-term follow-up of 500 patients.  Trans Am Ophthalmol Soc. 1994;  92 271-287
  • 40 Shin J P, Lee J W, Sohn B J, Kim H K et al. In vivo corneal endothelial safety of intracameral bevacizumab and effect in neovascular glaucoma combined with ahmed valve implantation.  J Glaucoma. 2009;  18 589-594
  • 41 Sidoti P A, Dunphy T R, Baerveldt G et al. Experience with the Baerveldt glaucoma implant in treating neovascular glaucoma.  Ophthalmology. 1995;  102 1107-1118
  • 42 Sivak-Callcott J A, O'Day D M, Gass J D et al. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma.  Ophthalmology. 2001;  108 1767-1776 quiz 1777 1800
  • 43 Takihara Y, Inatani M, Fukushima M et al. Trabeculectomy with mitomycin C for neovascular glaucoma: prognostic factors for surgical failure.  Am J Ophthalmol. 2009;  147 912-918
  • 44 Tsai J C, Feuer W J, Parrish R K et al. 5-Fluorouracil filtering surgery and neovascular glaucoma. Long-term follow-up of the original pilot study.  Ophthalmology. 1995;  102 887-893
  • 45 Tsai J C, Wand M. Neovascular glaucoma. Albert AM, Miller J Principles and practice of ophthalmology. Philadelphia; Elsevier 2008: 2689-2712
  • 46 Uram M. Ophthalmic laser microendoscope ciliary process ablation in the management of neovascular glaucoma.  Ophthalmologie. 1992;  99 1823-1828
  • 47 Vasudev D, Blair M P, Galasso J et al. Intravitreal bevacizumab for neovascular glaucoma.  J Ocul Pharmacol Ther. 2009;  25 453-458
  • 48 Wakabayashi T, Oshima Y, Sakaguchi H et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.  Ophthalmologie. 2008;  115 1571-1580
  • 49 Yazdani S, Hendi K, Pakravan M et al. Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial.  J Glaucoma. 2009;  18 632-637
  • 50 Yildirim N, Yalvac I S, Sahin A et al. A comparative study between diode laser cyclophotocoagulation and the Ahmed glaucoma valve implant in neovascular glaucoma: a long-term follow-up.  J Glaucoma. 2009;  18 192-196

Priv.-Doz. Dr. med. Randolf A. Widder

Augenklinik St. Martinus-Krankenhaus

Gladbacher Straße 26

40219 Düsseldorf

Email: r.widder@martinus-duesseldorf.de